Aska Pharmaceutical Co

Aska Pharmaceutical Co, headquartered in Japan and operating in the Pharmaceutical Preparation Manufacturing industry, reported its most recent carbon emissions for 2022. The company's total reported emissions for 2022 were 10,780,000 kg CO2e, comprising 6,687,000 kg CO2e from Scope 1 emissions and 4,093,000 kg CO2e from Scope 2 emissions.

This represents a reduction from 2021, where total reported emissions were 12,251,000 kg CO2e (7,209,000 kg CO2e Scope 1 and 5,042,000 kg CO2e Scope 2). In 2020, total reported emissions were 13,215,000 kg CO2e (7,443,000 kg CO2e Scope 1 and 5,771,000 kg CO2e Scope 2).

Aska Pharmaceutical Co has not disclosed Scope 3 emissions data, indicating a potential area for further transparency in its climate commitments. No specific reduction targets, including SBTi targets or participation in the Climate Pledge, have been publicly reported. Emissions data for Aska Pharmaceutical Co are directly reported by the company, not cascaded from a parent or related organization.